Retrophin, Inc. (NASDAQ:RTRX)

CAPS Rating: 2 out of 5

Results 1 - 4 of 4

Recs

1
Member Avatar TSIF (99.96) Submitted: 7/27/2014 6:19:21 PM : Outperform Start Price: $10.11 RTRX Score: +7.60

Retrophin, Inc has been even more erratic than most of the biopharm during the derisk cycle that pulled many down after the group had had a somewhat "bubbling" experience. It doesn't take many like Puma Biotech that soared closed to 300% this week to get the attention of speculators. Valuing early stage biotechs is pretty nigh impossible, as you have to determine the cost to complete trials, funds available, dilution, chance of success, time to success, market of the product if successful, companies ability to get sold for instant/maximum profit, versus bringing their own product to market without the manufacturing and sells skills in-house.

Retrophin has been especially volatile, and while my call is well in the green after only a few days, things could change tomorrow. Added to the chance of their drug portfolio, Retrophin has class action suits against it for not mentioning litigation against it in it's May 10-Q, yet $746k, or about 10% of assets was recently demanded. Small in the big scheme of things, but cash is precious at this stage of development.

Retrophin doubled from $10 to the mid-20's from Feb to April, starting with purchasing privately held Manchester Pharmaceuticals. Two FDA approved products should give Retrophin moderate, but not sufficient cash flow to use on it's own products. It's development list is too long to cite, fairly rare indices. It's RE-001, a therapy for the treatment of duchenne muscular dystrophy, dropped it back down to the $10 range.

Speculative, can't recommend. Caps play.

Recs

0
Member Avatar flomomomo (< 20) Submitted: 5/31/2014 5:18:25 AM : Outperform Start Price: $16.78 RTRX Score: -38.20

damn me i forgot to put a limit order...but still got the shares cheaper than the ceo

Recs

0
Member Avatar manirg (53.31) Submitted: 5/13/2014 2:10:53 PM : Outperform Start Price: $12.39 RTRX Score: -16.46

undervalued. CEO bot a lot shares at 15-18. Tremendous potential...

Recs

0
Member Avatar LaFemmeFool (< 20) Submitted: 3/13/2014 4:02:28 PM : Outperform Start Price: $17.54 RTRX Score: -45.12

insider buying + good stock

Results 1 - 4 of 4

Featured Broker Partners


Advertisement